Day: May 3, 2024

SAN FRANCISCO, May 03, 2024 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced that its management team will participate in the following four investor conferences in May and June 2024.RBC Capital Markets Global Healthcare Conference (New York): Management will participate in a fireside chat on May 15 at 10:30 a.m. ET, and be available for 1×1 investor meetings. The webcast link for the fireside chat can be found at https://ir.augmedix.com/. Benchmark Healthcare House Call Conference (Virtual): Management will be available for 1×1 investor meetings on May 21. B. Riley Annual Institutional Investor Conference (Beverly Hills, CA): Management will participate in a fireside chat on May 22 at 9:00 a.m. PT, and be available for 1×1 investor...

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class...

SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) —  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors. Guggenheim Healthcare Talks | Radiopharmaceuticals DayDate: Monday, May 13, 2024Location: New York, NY Format: Panel Discussion – Evolving Landscape of Radiopharmaceuticals in IndustryTime: Noon Format: Company PresentationTime: 2 p.m. ET 2024 RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 15, 2024Location: New York, NYFormat: Fireside ChatTime: 9.30 a.m. ET Bank...

OTTAWA, May 03, 2024 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, has scheduled a conference call on Friday, May 10, 2024 at 10:30 a.m. ET to discuss its financial results for the three month period ended March 31, 2024. The call will be hosted by Daniel S. Goldberg, President and Chief Executive Officer, and Andrew Browne, Chief Financial Officer, of Telesat. Prior to the commencement of the call, Telesat will post a news release containing its financial results on its website (www.telesat.com) under the tab “Investors” and the heading “Investor News”. Dial-in Instructions: The toll-free dial-in number for the teleconference is +1 800 806 5484. Callers outside of North America should dial +1 416 340 2217. The access code is 6484355 followed by the number...

LOS ANGELES, May 03, 2024 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products, today announced its entry into a distribution agreement (“Agreement”) with Kinsey’s Inc. to distribute AXIL hearing protection and enhancement products including AXIL GS Extreme 2.0®, XCOR®, XCOR Digital®, and the Trackr™ series hearing solutions. “Our partnership with Kinsey’s is an important step in providing retailers greater access to AXIL products. Kinsey’s has long been regarded a top tier distributor with the highest quality of service and business values. We are confident our partnership with Kinsey’s will provide AXIL dealers and retailers outstanding service and support,” said Jeff Toghraie,...

— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim, first-in-human clinical data from the ongoing Phase 1 trial of WTX-330 in the second quarter of 2024 — — Multiple presentations of preclinical data demonstrate the potential of the PREDATORTM platform, including in immunology-based diseases — — Company announces cash runway extension through at least the first quarter of 2026 — WATERTOWN, Mass., May 03, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other...

SHANGHAI, China, May 03, 2024 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology company, today announced the launch of multiple intelligent driving and safety features for its Skyland Pro computing platform, which significantly enhance the intelligent driving experience. The new features were previewed during ECARX’s second Tech Day, which was held in Hangzhou on March 20, 2024, and were released for the first time in the recent version 1.4.0 update for the “Lynk Co-Pilot Navi” smart navigation assistance system on Lynk & Co. 08 EM-P. Leveraging the power of Skyland Pro’s dual system-on-a-chip architecture, the update included a number of L2+ assisted driving and parking features, including highway Navigate-on-Autopilot (NOA), Automatic Parking Assist (APA), and...

– Trial did not meet primary endpoint – IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. The primary endpoint of mean reduction in monthly migraine days (MMD) over the period 13-24 weeks in a total of 325 analyzed patients randomized across three arms showed a reduction of 8.5 days in the 150 U arm and 7.7 days in the 195 U arm, compared with a reduction of 8.4 days in the placebo arm. These differences...

FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), and Steven Lin, M.D. (MD Anderson Cancer Center), who will discuss below topics:Plinabulin history and development strategy for cancer Plinabulin’s...